Patents by Inventor Feihong Ji

Feihong Ji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of a quinazoline compound in preparing a medicament against flaviviridae virus
    Patent number: 9133138
    Abstract: Disclosed is a use of a quinazoline compound of Formula I having 2,4-diaminoquinazoline as a parent nucleus in preparation of a medicament for treating diseases caused by flaviviridae infection, especially a use in combating Hepatitis C virus infection and Dengue fever virus infection.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: September 15, 2015
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Jianping Zuo, Youhong Hu, Wei Tang, Bo Chao, Xiankun Tong, Dewen Li, Feihong Ji, Peilan He
  • USE OF A QUINAZOLINE COMPOUND IN PREPARING A MEDICAMENT AGAINST FLAVIVIRIDAE VIRUS
    Publication number: 20130261139
    Abstract: Disclosed is a use of a quinazoline compound of Formula I having 2,4-diaminoquinazoline as a parent nucleus in preparation of a medicament for treating diseases caused by flaviviridae infection, especially a use in combating Hepatitis C virus infection and Dengue fever virus infection.
    Type: Application
    Filed: December 2, 2011
    Publication date: October 3, 2013
    Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Jianping Zuo, Youhong Hu, Wei Tang, Bo Chao, Xiankun Tong, Dewen Li, Feihong Ji, Peilan He
  • Pharmaceutical Use of 2',2-Bis-Thiazole Non-Nucleoside Compounds as Hepatitis C Virus Inhibitor
    Publication number: 20120264793
    Abstract: The present invention discloses the pharmaceutical use of a 2?,2-bis-thiazole non-nucleoside compound of formula I as an inhibitor of hepatitis C virus (HCV). The 2?,2-bis-thiazole non-nucleoside compound can inhibit the replication of HCV, and thus has an anti-HCV activity and is useful for treating hepatitis C.
    Type: Application
    Filed: November 24, 2010
    Publication date: October 18, 2012
    Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Fajun Nan, Jianping Zuo, Yangming Zhang, Feihong Ji, Haijun Chen, Xiankun Tong